LIGAND PHARMACEUTICALS INC Cash Flow Statement
LGNDZ|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
LIGAND PHARMACEUTICALS INC generated $49M in operating cash flow and $49M in free cash flow in FY2025. Free cash flow margin was 18.2% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $124.5M | -$4.0M | $52.2M | -$33.4M | $57.1M | -$3.0M | $629.3M | $143.3M | $12.6M | -$1.6M | $229.8M | $12.0M | $11.4M | -$527.0K | $9.7M |
| Depreciation & Amortization | $33.8M | $35.2M | $36.5M | $51.5M | $51.1M | $25.7M | $18.4M | $12.8M | $11.0M | $11.3M | $2.6M | $2.7M | $2.7M | $2.7M | $2.8M |
| Operating Cash Flow | $49.4M | $97.0M | $49.6M | $137.8M | $78.8M | $54.6M | -$29.3M | $194.1M | $88.6M | $60.7M | $41.7M | $20.6M | $20.7M | $161.0K | -$1.2M |
| Capital Expenditures | $452.0K | $1.8M | $3.5M | $17.9M | $8.8M | $4.5M | $2.6M | $887.0K | $2.2M | $1.9M | $93.0K | $6.0K | $377.0K | $595.0K | $78.0K |
| Free Cash Flow | $48.9M | $95.2M | $46.1M | $119.9M | $70.0M | $50.1M | -$31.9M | $193.2M | $86.4M | $58.9M | $41.6M | $20.6M | $20.3M | -$434.0K | -$1.3M |
| Share Buybacks | $15.0M | $0 | $0 | $0 | $0 | $78.0M | $453.0M | $122.9M | $2.0M | $3.9M | $489.0K | $68.0M | $0 | $0 | $55.0K |
| FCF Margin | 18.2% | 57.0% | 35.1% | 61.1% | 29.0% | 30.6% | -26.5% | 76.8% | 295.3% | 54.0% | 57.9% | 31.9% | 41.5% | -1.4% | -4.2% |